| Therapeutic Modalities | Number (n) | % | Post therapeutic clinical response (%) | |||||
| Pain | Cough | Dysp | Hemop | PNS | ||||
| Surgery (Radical or partial) | 3 | 4 | 4 | 0 | 0 | 0 | 3 | |
| Surgery + Chemo | 6 | 8 | 4 | 0 | 1 | 0 | 2 | |
| Radiotherapy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Chemo (6 cures) | Taxane + Platine | 21 | 27 | 2 | 0 | 0 | 0 | 1 |
| Navelbine + Platine | 11 | 14 | 3 | 0 | 1 | 0 | 0 | |
| 5FU + Platine | 23 | 30 | 4 | 1 | 0 | 1 | 0 | |
| Target Therapies | Erlotinib | 2 | 3 | 0 | 0 | 0 | 0 | 0 |
| Taxane + Bevacizumab | 1 | 1 | 1 | 0 | 0 | 0 | 2 | |
| Palliatif care | 10 | 13 | 5 | 4 | 1 | 0 | 3 | |
| Total | 77 | 100 | 23 | 5 | 3 | 1 | 11 | |